Hematology

The Division of Hematology was founded in 1938 by Carl V. Moore, M.D., and the three main goals established at its inception -- research, teaching and clinical care -- remain in place today.

The Division of Hematology employs full-time faculty members who epitomize excellence in basic and clinical science. The focus of the Division is on non-malignant disorders including diseases of red blood cells, platelets, and the coagulation and fibrinolytic pathways.

News Stories & Tip Sheets:

Showing Stories 1 through 3 of 16.  - Show More

Nutrients help reduce risk of birth defects Some neural tube defects in mice linked to enzyme deficiency May 25, 2009 -- Women of childbearing age can reduce the risk of having a child born with a neural tube defect such as spina bifida by eating enough folate or folic acid. However, folate prevents only about 70 percent of these defects. New research using mice at the School of Medicine confirms the importance of another nutrient, inositol, to protect against the development of neural tube defects.

Blood donation awareness Church effort sharply increases first-time African-American blood donors Dec. 15, 2008 -- A program at the School of Medicine and St. Louis Children's Hospital designed to increase awareness about sickle cell disease and the importance of blood donations within the African-American faith community led to a 60 percent increase in first-time blood donations, a new study has found.

Treating sickle cell with stem cells Stem cell transplant for sickle cell disease subject of clinical trial July 11, 2008 -- Children with sickle cell disease often face severe pain, organ damage, recurrent strokes and repeated, prolonged hospital stays. Although there are medical interventions that can lessen the symptoms, there is no cure. Researchers at the School of Medicine are leading a nationwide, multicenter clinical trial to determine the effectiveness of transplanting blood stem cells from unrelated donors into children with severe sickle cell disease.

Showing Stories 1 through 3 of 16.  - Show More

Faculty Experts:

Showing 1 Experts.

John DiPersio Chief of the Division of Bone Marrow Transplantation and Stem Cell Biology DiPersio helped pioneer stem cell transplants and now focuses his research efforts on improving the success of bone marrow and stem cell transplants for the treatment of cancer and disorders of the blood. He is investigating the use of gene therapy to control graft versus host disease that is a main ... Expertise: bone marrow transplantation, leukemia/lymphoma, stem cell transplantation, graft vs. host disease Media assistance: (314) 286-0141 / ericsong@wustl.edu

Showing 1 Experts.

Related News Clips:

Showing 3 Clips.

J&J, Bayer, Boehringer Clot-Busters May Reap Billons Bloomberg.com and 1 others Dec. 10, 2008 -- The first new pills in 60 years to prevent vein-clogging clots are emerging from research laboratories and may bring billions of dollars in sales to Johnson & Johnson, Bayer AG and Boehringer Ingelheim GmbH. WUSTL hematology professor Evan Sadler comments.

Experts Decode Cancer Patient's Genes, Seeking Treatment Clues The New York Times and 57 others Nov. 6, 2008 -- For the first time, researchers have decoded all the genes of a person with cancer and found a set of mutations that might have caused the disease or aided its progression. Includes comments by Richard Wilson, senior study author and director of WUSTL's Genome Sequencing Center, and WUSTL hematologist Timothy Ley, director of the study.

'Bloodless' surgery offers an alternative to transfusion Detroit Free Press and 1 others June 3, 2004 -- A bloodless medicine program offers alternatives for those who do not want blood, and helps to save the supply for those who need it. "What is going to drive conservation of blood is inventory," said Lawrence Goodnough, M.D., professor of medicine at the School of Medicine. "We're kind of skating along with low inventories." Some people will always need donated blood, Goodnough said. "Who are we saving the blood supply for? For trauma cases or bone marrow transplants or newly diagnosed conditions and people who can't plan ahead." The best candidates for bloodless medicine are patients undergoing scheduled or elective procedures. These allow time to take the patient's blood count and make a treatment plan.

Washington University in St. Louis	School of Medicine
News & Information	Medical News